摘要
目的分析达比加群酯不良反应的发生规律和特点。方法通过检索CNKI、万方、VIP、PubMed、WebofScience、ScienceDirect、Scifinder等数据库,对国内外所有达比加群酯不良反应的个案报道、临床试验和研究进行回顾性分析。结果共收集17例案例。达比加群酯所致不良反应主要为出血(47.1%)和皮疹(41.2%),且ADR多发生于2周内(78.6%)。结论使用达比加群酯时,在服药的2周内,应加强对患者的临床观察和实验室检查,同时加强对患者的用药教育,尽可能降低其ADR发生率。
Objective To analyze the general patterns and characteristics of adverse drug reactions ( ADR) induced by dabigatran etexilate. Methods The case reports,clinical trials and studies on ADR of dabigatran etexilate were collected from CNKI,Wanfang,VIP,PubMed,Web of Science,Science Direct,Scifinder and other literature databases for retrospective analysis. Results Totally 17 cases were collected. Hemorrhage ( 47.1%) and rash ( 41. 2%) were the main drug adverse reactions caused by dabigatran etexilate,and the ADR mostly occurred within 2 weeks ( 78. 6%). Conclusion Clinical observation, laboratory examination and drug education should be strengthened to reduce the probability of ADR as much as possible during the period of taking dabigatran etexilate,especially within 2 weeks after medication.
作者
边原
于楠
郝梦琳
周杨林
BIAN Yuan;YU Nan;HAO Meng-lin;ZHOU Yang-lin(School of Medicine,University of Electronic Science and Technology of China,Chengdu 610054,China;Department of Pharmacy,Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital/Affiliated Hospital of University of Electronic Science and Technology of China,Personalized Drug Therapy Key Laboratory of Sichuan Province,Chengdu 610072,China)
出处
《实用药物与临床》
CAS
2019年第8期871-875,共5页
Practical Pharmacy and Clinical Remedies
基金
四川省卫生和计划生育委员会科研课题(16PJ479)
国家临床药学重点专科建设项目(30305030698)
四川省省级公益性科研院所基本科研业务专项课题(2018YSKY0017)
四川省医学会科研课题计划(S16070)
四川省人民医院院级科研基金临床研究及转化项目(2018LY09)
关键词
达比加群酯
药物不良反应
文献分析
Dabigatran etexilate
Adverse drug reactions
Literature analysis
